Related Experiment Videos

Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis

C T Hsueh1, C F Chiu, D P Kelsen

  • 1Department of Internal Medicine, China Medical College Hospital, Taichung, Taiwan. d7198@hpd.cmch.org.tw

Abstract

Insights

Mitomycin-C upregulates cyclooxygenase-2 (COX-2) as an antiapoptotic signal in gastric cancer cells. Inhibiting COX-2 enhances apoptosis, offering a new therapeutic strategy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Cyclooxygenase-2 (COX-2) plays a role in anti-apoptosis signaling pathways.
  • Protein kinase C (PKC) activation may be necessary for COX-2 induction.
  • Safingol (SAF), a PKC inhibitor, enhances apoptosis induced by mitomycin-C (MMC) in gastric cancer cells.

Purpose of the Study:

  • To investigate the role of COX-2 in mitomycin-C (MMC)-induced apoptosis in human gastric cancer MKN-74 cells.
  • To elucidate the relationship between PKC activation, COX-2 expression, and apoptosis.

Main Methods:

  • Western blot analysis was used to assess protein expression of COX-2, Bcl-2, and PKCalpha activation.
  • Apoptosis was quantified by Hoechst-33258 staining of condensed chromatin.
  • Northern blot analysis was performed to examine COX-2 mRNA levels.

Main Results:

  • MMC exposure led to increased COX-2 and Bcl-2 protein levels and PKCalpha activation.
  • PKCalpha activation preceded COX-2 induction, and inhibition of PKC with SAF blocked COX-2 upregulation.
  • Selective COX-2 inhibition with NS-398 significantly enhanced MMC-induced apoptosis by fivefold.

Conclusions:

  • Mitomycin-C upregulates COX-2, which functions as an antiapoptotic signal downstream of PKC.
  • Selective inhibition of COX-2 enhances MMC-induced apoptosis independently of PKC inhibition.
  • Targeting COX-2 presents a novel strategy to augment apoptosis in gastric cancer treatment.

Related Concept Videos